0.15Open0.15Pre Close0 Volume1.05K Open Interest25.00Strike Price0.00Turnover350.06%IV135.27%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.0750Delta0.0264Gamma71.27Leverage Ratio-0.0474Theta0.0001Rho5.35Eff Leverage0.0022Vega
Avadel Pharmaceuticals Stock Discussion
AVDL fell 25.2% to $8 shortly before 5 p.m. ET after the company announced that Q4 revenues will come in at $50 million – below the $52.7 million that analysts had reportedly expected.
The company like...
yeah, cluster buys drew my attention too
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challen...
🎃⚡️🎃
📊⚡️📊
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
No comment yet